MDPR
MDPR:
556,
579,
587
Braun, U; Shulgin, AT; Braun, G. Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J. Pharm. Sci., 1 Jan 1980, 69 (2), 192–195. 513 kB. https://doi.org/10.1002/jps.2600690220 #IId
Dal Cason, TA. An evaluation of the potential for clandestine manufacture of 3,4-methylenedioxyamphetamine (MDA) analogs and homologs. J. Forensic Sci., 1 May 1990, 35 (3), 675–697. 2.2 MB. https://doi.org/10.1520/JFS12874J
Braun, U; Shulgin, AT; Braun, G. Prüfung auf zentrale Aktivität und Analgesia von N-substituierten Analogen des Amphetamin-Derivates 3,4-Methylendioxyphenylisopropylamin. Arzneim. Forsch., 1 Jan 1980, 30 (5), 825–830. 1.5 MB. #IID
Noggle, FT; DeRuiter, J; Coker, ST; Clark, CR. Synthesis, identification, and acute toxicity of some N-alkyl derivatives of 3,4-methylenedioxyamphetamine. J. Assoc. Off. Anal. Chem., , 70 (6), 981–986. 1.8 MB. #2 LC,NMR,UV
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
Dal Cason, TA; Meyers, JA; Lankin, DC. Proton and carbon-13 NMR assignments of 3,4-methylenedioxyamphetamine (MDA) and some analogues of MDA. Forensic Sci. Int., 18 Apr 1997, 86 (1–2), 15-24. 1.0 MB. https://doi.org/10.1016/S0379-0738(97)02102-6 #N-(n-Propyl) MDA NMR
King, LA. New phenethylamines in Europe. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 808-818. 472 kB. https://doi.org/10.1002/dta.1570
Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Dal Cason, TA. The characterization of some 3,4-methylenedioxyphenylisopropylamine (MDA) analogs. J. Forensic Sci., 1 Jul 1989, 34 (4), 928–961. 734 kB. https://doi.org/10.1520/JFS12722J #4 Rhodium. GC,MS,NMR,IR
Sáez-Briones, P; Hernández, A. MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology. Curr. Neuropharmacol., 1 Sep 2013, 11 (5), 521–534. 1.4 MB. https://doi.org/10.2174/1570159X11311050007 #MDPR
N-Isopropyl-3,4-methylenedioxyamphetamine · N-Isopropyl-MDA · MDIP
N-Methyl-α-propyl-3,4-methylenedioxyphenethylamine · METHYL-K
L · α-Bu-MDPEA · α-Butyl-3,4-methylenedioxyphenethylamine
4-Ethenyl-2,5-dimethoxyamphetamine · DOV · DOVI
2,3-MMBDB · α-Ethyl-N,N-dimethyl-2,3-methylenedioxyphenethylamine
2,3-EBDB · N,α-Diethyl-2,3-methylenedioxyphenethylamine
N-Ethyl-N-methyl-3,4-methylenedioxyamphetamine · MDMEA
DMBDB · MMBDB · α-Ethyl-N,N-dimethyl-3,4-methylenedioxyphenethylamine
ATK-0104 · α-Isopropyl-N-methyl-3,4-methylenedioxyphenethylamine · α-iPr-N-Me-3,4-MDPEA
4-Allyl-3,5-dimethoxyphenethylamine · DAL
2C-CP · 4-Cyclopropyl-2,5-dimethoxyphenethylamine
2C-AL · 4-Allyl-2,5-dimethoxyphenethylamine
2,5-Dimethoxy-4-(1-methylvinyl)phenethylamine · 2C-1MV
2C-2MVE · trans-2,5-Dimethoxy-4-propenylphenethylamine
2C-2MVZ · cis-2,5-Dimethoxy-4-propenylphenethylamine
4-AlO-3-MA · 4-Allyloxy-3-methoxyamphetamine · ALOMA
4-MeO-NEB · 4′-Methoxy-2-(ethylamino)butanophenone